Introduction

Candida species rarely cause UTIs in healthy individuals. However, glucosuria due to poorly controlled diabetes mellitus (DM) has long been assumed as a risk factor for acquiring UTIs and genital yeast infections [1]. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are antidiabetic drugs that were introduced to the European market in 2012. These drugs lower blood glucose levels by causing the kidneys to excrete glucose into the urine and they are often used in the management of type 2 DM (T2DM). However, several studies have reported side-effects of SGLT-2 inhibitors, including UTIs and genital yeast infections [2]. In 2015, the United States Food and Drug Administration (FDA) warned about a potential risk of UTIs and thereby increased awareness of SGLT-2 inhibitor usage.

We present the case of a patient with diabetes who developed Candida parapsilosis fungaemia originating from the urinary tract, complicated by a fungus ball. This patient was previously treated with a SGLT-2 inhibitor.

中文翻译：

---

丹麦 Herlev 和 Gentofte 医院的“本月案例”：服用钠-葡萄糖协同转运蛋白 2 抑制剂的糖尿病患者出现念珠菌血症和真菌球

 介绍

念珠菌很少引起健康个体的尿路感染。然而，糖尿病（DM）控制不良导致的糖尿长期以来被认为是获得尿路感染和生殖器酵母菌感染的危险因素[ 1 ]。钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂是2012年引入欧洲市场的抗糖尿病药物。这些药物通过使肾脏将葡萄糖排泄到尿液中来降低血糖水平，常用于糖尿病管理2 型 DM (T2DM)。然而，一些研究报告了 SGLT-2 抑制剂的副作用，包括尿路感染和生殖器酵母菌感染 [ 2 ]。 2015 年，美国食品和药物管理局 (FDA) 警告了尿路感染的潜在风险，从而提高了人们对 SGLT-2 抑制剂使用的认识。

我们介绍了一名糖尿病患者的病例，该患者患有源自泌尿道的近平滑念珠菌真菌血症，并发真菌球。该患者之前接受过 SGLT-2 抑制剂治疗。